2026-07-30T09:33:51-05:00 2025-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2025-01-01 133870223 INTERNATIONAL AIDS VACCINE INITIATIVE INC INTE 2128471111 125 BROAD STREET 9TH FL NEW YORK NY 10004 BRANDON SAFT CFO 2128471111 2026-07-30 1 RICHARD J LOCASTRO CPA P00288314 3019519090 2025 2025-03-06 01:10:19Z IAVI MARK B FEINBERG 125 BROAD STREET 9TH FL NEW YORK NY 10004 110643253 0 X WWW.IAVI.ORG X 1996 DE TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS 14 13 239 13 0 0 126009254 99364861 2511798 1240434 2295284 2045077 365139 710297 131181475 103360669 33692633 27190529 0 0 50838786 43037681 0 0 168197 58512176 37097998 143043595 107326208 -11862120 -3965539 129852638 140571416 78459588 91790884 51393050 48780532 X A GLOBAL NONPROFIT BIOMEDICAL RESEARCH ORGANIZATION THAT DEVELOPS VACCINES AND ANTIBODIES FOR HIV, TUBERCULOSIS, AND EMERGING INFECTIOUS DISEASES. 0 0 91410252 27190529 1240434 RESEARCH AND DEVELOPMENT:THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC ( SEE SCHEDULE O FOR CONTINUATION) CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS, INCLUDING A VACCINE CANDIDATE THAT HAS YIELDED PROMISING EARLY RESULTS AND IS PART OF AN EXCITING NEW APPROACH TO HIV VACCINE DESIGN. OTHER NOTABLE ACHIEVEMENTS INCLUDE THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE HIV BURDEN IS GREATEST, AND THE FIRST TRIAL OF AN MRNA HIV VACCINE CANDIDATE IN AFRICA. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER, AND MARBURG, SUDAN, AND BUNDIBUGYO VIRUS DISEASES, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN LOW-INCOME COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST.IAVI ALSO SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS. 91410252 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 0 0 1 0 1 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 0 0 1 X 88 0 1 239 1 0 1 IN SF UK KE 0 0 0 0 0 0 0 0 0 0 X 14 13 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 X X X LAKHERAM SUKHDEO 2127635462 125 BROAD STREET 9TH FL NEW YORK NY 10004 MARK B FEINBERG PRESIDENT/CEO 35.00 X X 705773 0 61475 ERIC PAUL GOOSBY MD BOARD CHAIR 2.00 X X 0 0 0 ROBERT GOLDBERG BOARD TREASURER 2.00 X 0 0 0 LINDA- GAIL BECKER BOARD MEMBER 1.00 X 0 0 0 DAVID BLUMBERG BOARD MEMBER 1.00 X 0 0 0 JIM CONNOLLY BOARD MEMBER 1.00 X 0 0 0 ALEXIS M PINTO BOARD MEMBER 1.00 X 0 0 0 JOHN W SHIVER BOARD MEMBER 1.00 X 0 0 0 SUSAN SILBERMANN BOARD MEMBER 1.00 X 0 0 0 ANNE MARTIN SIMONDS BOARD MEMBER 1.00 X 0 0 0 RAJEEV VENKAYYA BOARD MEMBER 1.00 X 0 0 0 MARIJKE WIJNROKS BOARD MEMBER 1.00 X 0 0 0 HON MARK DYBUL BOARD MEMBER 1.00 X 0 0 0 WAFAA EL-SADR BOARD MEMBER 1.00 X 0 0 0 MARIO GAGLIANO CHIEF PEOPLE OFFICER, VP OF HR 35.00 X 367640 0 58899 MIN DING GENERAL COUNSEL / BOARD SECRETARY 35.00 X 357370 0 66089 BRANDON SAFT CHIEF FINANCIAL OFFICER 35.00 X 331727 0 41476 ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER (END 3/25) 35.00 X 169900 0 19086 LOUIS D SCHWARTZASST SEC CHF.FIN. & ADMIN OFF. (END 1/25) 35.00 X 3000 0 105 KARA BICKHAM CHIEF DEV. OFFICER- RESEARCH DEV. 35.00 X 414513 0 64206 SWATI GUPTA VP, HEAD OF EID AND EPIDEMIOLOGY 35.00 X 393577 0 51231 JON HEINRICHS VP, DISCOVERY SCIENCE 35.00 X 374045 0 57507 CHRISTOPHER PARKSASS VP VIRAL VACC. & HEAD OF DDL 35.00 X 376537 0 51372 RICHARD W WELCH VP, BIOPROCESS DEV. & MFG. 35.00 X 346345 0 43056 3840427 0 514502 163 0 1 0 EMMES CORPORATION 401 N WASHINGTON STREET SUITE 700 ROCKVILLE MD 20850 CLINICAL RESEARCH STUDIES 1140283 WCH PTY LTD (CLS) 31 PRINCESS OF WALES TERRACE JHB SF 02193 LEGAL SERVICES 854117 DUANE MORRIS LLP 30 SOUTH 17TH STREET PHILADELPHIA PA 19103 PROGRAM CONSULTANT SERVICES 574741 US MEDIC EQUIP CONSLT 5601 NORTHWEST 72ND ST STE 324 WARR ACRES OK 73132 EQUIPMENT MAINTENANCE 369625 GRF CPAS & ADVISORS 4550 MONTGOMERY AVE STE 800 N BETHESDA MD 20418 AUDITORS 320397 8 1665835 40186480 57512546 50232 99364861 CONTRACT SERVICE FEES 900099 1240434 1240434 1240434 1902661 1902661 7425000 7282584 142416 142416 142416 ACCRUAL WRITE OFF 900099 321065 321065 REFUND 900099 291436 291436 ROA LEASE ADJ. 900099 82193 82193 15603 15603 710297 103360669 1240434 0 2755374 6170405 6170405 21020124 21020124 2182540 345857 1836683 32244204 21807080 10377326 59798 2457720 2457720 3540418 3499821 40597 2612799 2612799 271027 271027 296518 296518 100000 100000 68418 68418 1762272 1150332 611940 614037 269894 344143 1580496 1084258 496238 7904955 6779800 1125155 964607 816578 139630 8399 20 49009 -48989 384009 350055 33954 377323 329567 47756 RESEARCH&CLINICAL SVCS 19606633 19546788 59845 LAB SUPPLIES/EQUIPMENT 2320882 2320882 EQUIPMENT MAINT. 485430 485430 LICENSES & FEES 138836 128578 10258 222535 185275 37260 107326208 91410252 15747759 168197 18632887 22425012 43074450 55697029 219130 441547 241274 248572 48099652 47643500 841193 456152 36526217 31695203 30317487 29607901 129852638 140571416 7911112 7706583 9292944 11547500 31126467 40150950 30129065 32385851 78459588 91790884 X 27604225 12868722 23788825 35911810 51393050 48780532 129852638 140571416 X -3965539 28877 1324144 X 0 1 X 1 1 1 X 122787618 143987755 124587673 126009254 99364861 616737161 122787618 143987755 124587673 126009254 99364861 616737161 177662030 439075131 613689 751530 3256766 2365037 1902661 8889683 171107 403411 31028 365139 710297 1680982 627307826 10301362 0.69990 0.72090 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2021 AMOUNT: $ 103,555. 2022 AMOUNT: $ 403,411. 2023 AMOUNT: $ 31,028. 2024 AMOUNT: $ 86,894. 2025 AMOUNT: $ 15,603. DATA DEF BUILD OUT - 2024 AMOUNT: $ 150,000. PROPERTY REASSESS - 2024 AMOUNT: $ 128,245. DDL MOVE - 2025 AMOUNT: $ 321,065. LOAN FORGIVENESS - 2021 AMOUNT: $ 67,552. REFUND - 2025 AMOUNT: $ 291,436. ROU ADJUSTMENT - 2025 AMOUNT: $ 82,193. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 100000 100000 107157790 107257790 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 247500 225000 180000 100000 752500 250000 250000 250000 250000 1000000 1500000 20305061 20172731 132330 27794591 27470769 323822 456152 SECURITY DEPOSITS 162820 LOAN & EXCHANGE 4112 RIGHT-OF-USE ASSETS 29440969 29607901 OPERATING LEASE LIABILITIES 31779134 DEFERRED COMPENSATION PAYABLE 606717 32385851 103479144 28877 459470 488347 102990797 68418 301454 369872 103360669 107501513 12868968 12868968 94632545 68418 12625245 12693663 107326208 PART XI, LINE 2D - OTHER ADJUSTMENTS: REVENUE OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 117,283. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. REVENUE OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 142,127. REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. REVENUE OF IAVI-SA, INCLUDED IN CONSOLIDATED AUDIT 64,520. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. REVENUE OF IAVI-AFRICA, INCLUDED IN CONSOLIDATED AUDIT 135,540. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XI, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY REVENUE, ELIMINATED IN CONSOLIDATED AUDIT 301,454. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. PART XII, LINE 2D - OTHER ADJUSTMENTS: EXPENSES OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 3,084,435. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 201,637. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI-SA, INCLUDED IN CONSOLIDATED AUDIT 5,155,065. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI-AFRICA, INCLUDED IN CONSOLIDATED AUDIT 4,427,831. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XII, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY GRANT EXPENSES, ELIMINATED IN CONSOLIDATED 12,625,245. AUDIT REPORT BUT INCLUDED IN IAVI, INC. FORM 990. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 3650608 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 16397 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 17091415 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 261705 NORTH AMERICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 183627 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 90878 EUROPE (INCLUDING ICELAND & GREENLAND) 1 16 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 4620682 EAST ASIA AND THE PACIFIC 1 14 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 525380 SOUTH ASIA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 34074 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 2977905 30 30 0 0 30 30 26440692 3011979 29452671 MIDDLE EAST AND NORTH AFRICA RESEARCH&DEVELOPMENT 170827 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 97158 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 16466 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 195947 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 155647 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 350611 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 2768788 WIRE TRANSFER 0 SOUTH ASIA RESEARCH&DEVELOPMENT 16397 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 782329 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 547758 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 303947 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 103670 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 496681 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 83495 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 1496223 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 208830 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 733703 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 93691 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 389454 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 230000 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 46481 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 184939 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 782706 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 348061 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 164952 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 224850 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 228166 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 12395 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 5257004 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 4298000 WIRE TRANSFER 0 22 8 RESEARCH CONSULTING EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIU 1 7500 WIRE TRANSFER RESEARCH CONSULTING EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIU 1 58490 WIRE TRANSFER RESEARCH CONSULTING SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 1 9600 WIRE TRANSFER RESEARCH CONSULTING SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 1 22550 WIRE TRANSFER RESEARCH CONSULTING SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 1 41929 WIRE TRANSFER RESEARCH CONSULTING MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 1 90878 WIRE TRANSFER 1 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. ROUTINE COMPLIANCE AND SUBSTANTIVE AUDITS ARE PERFORMED BY A COMPLIANCE OFFICER LOCATED IN EAST AFRICA. ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. 1 THE SCRIPPS RESEARCH INSTITUTE - OSP 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 2460785 0 RESEARCH & DEVELOPMENT FHI CLINICAL INC 359 BLACKWELL STREET SUITE 200 DURHAM NC 27701 237413005 501(C)(3) 1216365 0 RESEARCH & DEVELOPMENT THE MITCHELL GROUP INC (TMG) 1816 11TH STREET NW WASHINGTON DC 20001 521467119 922886 0 RESEARCH & DEVELOPMENT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 910961784 501(C)(3) 673716 0 RESEARCH & DEVELOPMENT TRUSTEES OF BOSTON UNIVERSITY TRUSTEES OF BOSTON UNIVERSITY 881 COMMONWEALTH AVENUE BOSTON MA 02115 042103547 501(C)(3) 413903 0 RESEARCH & DEVELOPMENT LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 501(C)(3) 400557 0 RESEARCH & DEVELOPMENT EMORY UNIVERSITY 1599 CLIFTON ROAD ATLANTA GA 30332 580566256 501(C)(3) 43165 0 RESEARCH & DEVELOPMENT SUNY GRADUATE SCHOOL 110 STATE STREE ALBANY NY 12236 146013200 501(C)(3) 39028 0 RESEARCH & DEVELOPMENT 7 1 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. REVIEW OF 2 CFR 200 AUDITS AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. X X X X 0 0 0 0 0 0 0 1 0 MARK B FEINBERG PRESIDENT/CEO 594115 0 49658 0 62000 0 60550 0 925 0 767248 0 0 0 KARA BICKHAM CHIEF DEV. OFFICER- RESEARCH DEV. 375077 0 8986 0 30450 0 31500 0 32706 0 478719 0 0 0 SWATI GUPTA VP, HEAD OF EID AND EPIDEMIOLOGY 335454 0 24949 0 33174 0 35824 0 15407 0 444808 0 0 0 JON HEINRICHS VP, DISCOVERY SCIENCE 321444 0 22101 0 30500 0 33600 0 23907 0 431552 0 0 0 CHRISTOPHER PARKSASS VP VIRAL VACC. & HEAD OF DDL 314865 0 23142 0 38530 0 33228 0 18144 0 427909 0 0 0 MARIO GAGLIANO CHIEF PEOPLE OFFICER, VP OF HR 328729 0 26911 0 12000 0 33488 0 25411 0 426539 0 0 0 MIN DING GENERAL COUNSEL / BOARD SECRETARY 304121 0 23249 0 30000 0 33383 0 32706 0 423459 0 0 0 RICHARD W WELCH VP, BIOPROCESS DEV. & MFG. 315345 0 0 0 31000 0 22313 0 20743 0 389401 0 0 0 BRANDON SAFT CHIEF FINANCIAL OFFICER 285633 0 16320 0 29774 0 29867 0 11609 0 373203 0 0 0 ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER (END 3/25) 108869 0 38694 0 22337 0 12272 0 6814 0 188986 0 0 0 PART I, LINE 7 MERIT-BASED BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). X 1 50232 FMV 0 0 0 0 PART I, COLUMN (B): THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS REVIEWED IN DETAIL BY THE CONTROLLER AND CFO AGAINST THE AUDITED FINANCIAL STATEMENTS BEFORE FILED WITH THE IRS. PLEASE NOTE THAT THE FINANCIAL STATEMENTS ARE FIRST REVIEWED AND APPROVED BY THE AUDIT AND FINANCE COMMITTEE AND SHARED WITH THE FULL BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C IAVI HAS A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES, CONSULTANTS AND ADVISORY COMMITTEE MEMBERS. THE POLICY REQUIRES THAT ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES AND ADVISORY COMMITTEE MEMBERS FILE AN ANNUAL DISCLOSURE FORM, INDICATING WHETHER THERE ARE ANY POSSIBLE OR ACTUAL CONFLICTS AS DEFINED UNDER THE POLICY. IN ADDITION, ALL ARE REQUIRED TO DISCLOSE ANY POSSIBLE OR ACTUAL CONFLICTS ON AN ONGOING BASIS. ANNUAL DISCLOSURE FORMS, AS WELL OTHER CONFLICT OF INTEREST DISCLOSURES THAT ARISE DURING THE YEAR, ARE FILED WITH AND REVIEWED BY THE GENERAL COUNSEL'S OFFICE. IN ADDITION, THE AUDIT & FINANCE COMMITTEE REVIEWS CONFLICT OF INTEREST DISCLOSURES THAT INVOLVE A DIRECTOR, OFFICER, OR KEY PERSON. IN EACH CASE, THE REVIEW ENSURES THAT ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST IS PROPERLY ADDRESSED, MITIGATED, AND/OR MANAGED. CONFLICT OF INTEREST DISCLOSURES ARE SUMMARIZED AND PROVIDED TO THE CHAIR OF THE AUDIT & FINANCE COMMITTEE FOR REVIEW BY THE AUDIT & FINANCE COMMITTEE. IF ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST DISCLOSURE INVOLVES THE CHAIR OF THE AUDIT & FINANCE COMMITTEE, THE COMMITTEE MEETS WITHOUT THE CHAIR. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD CAN PERIODICALLY COMMISSION A COMPENSATION SURVEY OF THE CEO'S COMPENSATION PACKAGE. WHEN DONE THIS SURVEY COMPARES COMPENSATION PACKAGES OF CEOS OF ORGANIZATIONS THAT ARE COMPARABLE TO IAVI. THEN THE COMMITTEE REVIEWS THE RESULTS AND MAKES RECOMMENDATIONS, DISCUSSES THIS WITH THE BOARD BEFORE PROVIDING SPECIFIC GUIDANCE AND APPROVAL TO IAVI'S MANAGEMENT.THE COMPENSATION COMMITTEE DETERMINES THE APPROPRIATE PACKAGE FOR THE CEO AND THE BOARD CHAIR SHARES THIS INFORMATION WITH HUMAN RESOURCES FOR IMPLEMENTATION. IAVI MAKES USE OF DATA FROM A SPECIALIZED COMPENSATION FIRMS TO CONDUCT THE SURVEY AND PROVIDES RECOMMENDATION TO THE COMPENSATION COMMITTEE. THE DELIBERATIONS OF THE COMPENSATION COMMITTEE OF THE BOARD ARE DOCUMENTED IN THE COMPENSATION COMMITTEE MINUTES FOR EACH MEETING OF THE MEMBERS. ALSO, THE SAME IS CAPTURED IN THE BOARD MINUTES AS REPORTED OUT BY THE COMPENSATIONCOMMITTEE CHAIR FOR BOARD DISCUSSIONS AND APPROVAL. THE LAST COMPENSATION REVIEW TOOK PLACE IN FEBRUARY 2025. THE COMMITTEE HAD NOT REQUESTED A COMPENSATION SURVEY SPECFIC TO CEO PAY SINCE INSTEAD CEO COMPENSATION WAS CONSIDERED IN THE SAME CONETEXT AND UNDER THE SAME CONDITIONS AS OTHER POSITIONS AT IAVI. IN DOING SO, IAVI USED EXTENRAL DATA SOURCES TO DETERMINE THE MARKET CHANGE IN THE COST OF LABOR, IAVI'S CURRENT MARKET COMPETITVNESS, AND AVAIABLE FUNDS TO DETERMINE PAY DECISIONS INDEPENDENT OF LEVEL OF STAFF OR OTHER KEY PERSONNEL. THE COMMITTEE REVIEWS THESE RESULTS AND RECOMMENDATIONS FROM THESE SOURCES AND PROVIDES MANAGEMENT WITH SPECIFIC GUIDANCE IN ADDRESSING ANY DISPARITIES. USING BENCHMARK JOB CLASSIFICATIONS, IAVI PURCHASES EXTERNAL SALARY SURVEY DATA, AND USES THIS DATA ACROSS ALL ITS OFFICES TO DETERMINE THE COMPETITIVENESS OF ITS COMPENSATION PROGRAMS AND TO ENABLE THE ORGANIZATION TO CONTINUE TO ATTRACT AND RETAIN THE RIGHT TALENT IN THESE VARIOUSMARKETS. IN MOST CASES THE LOCAL LABOR MARKET IS CONSIDERED AND FOR CERTAIN POSITIONS, REGIONAL MARKETS MUST BE TARGETED. SALARY RECOMMENDATIONS AND EXTERNAL DATA TRENDS MAY BE REVIEWED WITH THE COMPENSATION COMMITTEE OF THE BOARD, WHICH GIVES MANAGEMENT OVERALL GUIDANCE ON COMPENSATION DIRECTION. BASED ON RECOMMENDATIONS AND GUIDANCE OF THE COMPENSATION COMMITTEE, THEEXECUTIVE OFFICE AND HUMAN RESOURCES COMMUNICATE CHANGES TO ANY AFFECTED EMPLOYEES.ANY COMPENSATION CHANGES ARE DETERMINED BASED ON EXTERNAL COMPETIVENESS,RELATIVE INTERNAL VALUE, INDIVIDUAL PERFORMANCE, TEAM DYNAMIC, AND IAVI'S ABILITY TO PAY. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE ON ITS WEBSITE. FORM 990, PART XI, LINE 9: FOREIGN EXCHANGE GAIN 2,833,155. CURRENCY TRANSLATION 118,048. DE-OBLIGATION OF FUNDS -1,627,059. IAVI LAB LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262031769 LAB RESEARCH DE IAVI INC IAVI GLOBAL HEALTH IMPACT LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 FACILITATE PRODUCT DEVELOPMENT AND/OR COMMERCIALIZATION DE IAVI INC STICHTING IAVI VAN DIEMENSTRAAT 48 1013 NH AMSTERDAM NL RESEARCH SUPPORT NL N/A N/A IAVI INC 1 IAVI INDIA 4 FACTORY ROAD GROUND FLOOR ANSARI NAGAR WEST NEW DELHI-110029 IN RESEARCH SUPPORT IN N/A N/A IAVI INC 1 IAVI SOUTH AFRICA NPC (IAVI-SA) BLACK RIVER PARK 2 FIR ST OBSERVA CAPETOWN SF RESEARCH SUPPORT SF N/A N/A IAVI INC 1 IAVI AFRICA LIMITED 11TH FL MUTHANGARI DR PO BOX 340 NAIROBI KE RESEARCH SUPPORT KE N/A N/A IAVI INC 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 STICHTING IAVI B 2768788 ACTUAL IAVI SOUTH AFRICA NPC B 5257004 ACTUAL IAVI-INDIA C 1665385 ACTUAL IAVI AFRICA LIMITED B 4298000 ACTUAL